The conversation is about hair loss affecting motivation to work out. The original poster is using dutasteride and minoxidil and is considering a hair transplant.
A 20-year-old is feeling depressed about hair loss despite using minoxidil and finasteride for 5-6 months. Users suggest continuing treatment, trying derma rolling, oral minoxidil, and addressing lifestyle factors.
Users discussed hair loss treatments, specifically minoxidil and finasteride. They shared personal experiences and advice on starting these treatments early.
A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.
The user shared a two-year hair regrowth update after using 1mg Finasteride daily and Minoxidil liquid once daily, with significant improvement and no side effects. Some users suggested adding derma rolling to the regimen, while others discussed the effectiveness of Finasteride alone before considering Minoxidil.
A user sharing their positive experience with taking finasteride as part of their hair loss treatment regimen, which also included biotin, Nizoral Shampoo, OGX Biotin & Collagen Shampoo, and iRestore Laser Cap. Others shared their own experiences and advice on treating hair loss.
A drug that regrows body parts, but not hair, sparking debate on hair loss treatments. Discussions include the use of finasteride, dutasteride, and the potential for new methods to restore hair.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.
Dutasteride is praised for improving skin and hair regrowth, with fewer side effects than finasteride. Users report mixed results on shedding and regrowth, with some experiencing enhanced libido and skin quality.
PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
A new therapy aimed at destroying DHT receptors in the scalp is still in early trials and may take at least 5 years to become available. A sugar-like solution similar to Minoxidil is also in early testing stages and not yet commercialized.
The user is concerned about the interaction between dutasteride and ketoconazole, leading them to stop using ketoconazole shampoo, which has resulted in an oily and painful scalp. They are unsure whether ketoconazole increases or decreases the potency of dutasteride.
A new drug can regrow teeth, but hair loss treatments like Minoxidil, finasteride, and RU58841 are still being developed. Users express hope for future advancements and discuss the importance of mental health and the potential profitability of hair loss solutions.
The user experienced significant hair regrowth after switching from finasteride and minoxidil to dutasteride. They believe dutasteride is highly effective for treating hair loss.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Minoxidil increases hair count despite high prolactin being linked to hair loss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.
Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
Finasteride and minoxidil help maintain hair and slightly improve hairlines but are less effective at regrowing hair in bald areas, often needing a hair transplant for full restoration. Many users report no side effects and wish they had started treatment earlier.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.